Arrowhead Pharmaceuticals Inc [ARWR] stock is trading at $29.42, up 2.62%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARWR shares have gain 6.09% over the last week, with a monthly amount glided 43.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] stock has seen the most recent analyst activity on June 05, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $31. Previously, BofA Securities started tracking the stock with Buy rating on December 04, 2023, and set its price target to $29. On September 19, 2023, Citigroup initiated with a Neutral rating and assigned a price target of $33 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. SVB Securities downgraded its rating to a Market Perform but $40 remained the price target by the analyst firm on May 12, 2023. SMBC Nikko started tracking with a Outperform rating for this stock on April 26, 2023, and assigned it a price target of $80. In a note dated April 12, 2023, SVB Securities upgraded an Outperform rating on this stock and boosted its target price from $21 to $35.
Arrowhead Pharmaceuticals Inc [ARWR] stock has fluctuated between $9.57 and $31.13 over the past year. Currently, Wall Street analysts expect the stock to reach $32.44 within the next 12 months. Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] shares were valued at $29.42 at the most recent close of the market. An investor can expect a potential return of 10.27% based on the average ARWR price forecast.
Analyzing the ARWR fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.41 and Total Capital is -0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Arrowhead Pharmaceuticals Inc’s Current Ratio is 4.87. Also, the Quick Ratio is 4.87, while the Cash Ratio stands at 0.67. Considering the valuation of this stock, the price to sales ratio is 7.10, the price to book ratio is 7.78.
Transactions by insiders
Recent insider trading involved Hamilton James C, Chief Medical Officer, that happened on Sep 12 ’25 when 15000.0 shares were sold. Officer, Hamilton James C completed a deal on Sep 12 ’25 to buy 15000.0 shares. Meanwhile, Chief Medical Officer Hamilton James C sold 15000.0 shares on Sep 02 ’25.
